● The company, a spinoff of the BSC, employs a 23-member Team to Create “Digital Twins” of Human Organs, Enhancing the Speed of New Drug Clinical Trials

Barcelona, January 22, 2024 – ELEM Biotech, a virtual human technology founded in 2018, traces its origins to a groundbreaking initiative at the Barcelona Supercomputing Center. It has set up its headquarters at Pier07, a health hub supported by Tech Barcelona.

ELEM CEO Christopher Morton and CTO Mariano Vazquez, the founders of ELEM, aim to change how clinical trials are conducted by transforming the conventional approach to testing with animals and humans, thereby mitigating risks associated with the development of new therapeutics and fostering innovation.

The ELEM team currently consists of 23 members and is expanding. The dynamic technical team of ELEM combines diverse expertise, including biomedical, engineering, and computer science, crucial to the advancement of ELEM technology.

ELEM’s expansion plan is part of its ELVIS (ELEM Virtual Heart Populations for Supercomputers) project, which initiated in March 2023 and received the maximum funding available by the prestigious European Innovation Council (EIC) programme. Before this, the company successfully concluded a crowdfunding round with Capital Cell.

The relocation to Pier07 represents a strategic move for ELEM to reinforce its values to support the company’s ambitious growth plan for 2024 and beyond, anticipating significant milestones in product sales that will define its trajectory in the industry.

In 2023, ELEM reached new heights by expanding its Virtual Humans database to embrace pathological hearts, including conditions such as heart failure or ischemia. This strategic enhancement aims to support cardiac safety assessments throughout all phases of the clinical development process.

ELEM Biotech also closed the loop by introducing its product, V. HEART. This means the clients can now securely and independently perform virtual cardiac safety trials for new and existing molecules.

Christopher Morton, CEO of ELEM, expresses enthusiasm about the company’s successful engagement with global pharmaceutical and device companies. He highlights establishing valuable collaborations with medical professionals, clinicians, and hospitals. These partnerships have been cultivated through direct initiatives and support from appreciative organisations such as Tech Barcelona and the Barcelona Supercomputing Centre, guiding our trajectory and shaping our future.

Tech Barcelona is the independent, private, and nonprofit association that fosters the digital and technological ecosystem. Tech Barcelona’s commitment to the health sector is centered around Pier07, a leading hub for business innovation in the health and life sciences sector. Located at Via Laietana 26, the building houses startups and investors, as well as pharmaceutical companies, institutions, universities, research centers, and the public health system, all of which have representation and active participation in the contents and activities of Tech Barcelona. The space is part of the Urban Tech Campus project, a network of connected buildings designed to integrate innovation and technology into the city.